Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 11/20 | 0.46 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16532579 | 0.90 | MAP3K14 (0.45) | ELANEMAP3K14ALDH1A1NPSR1ADORA1 | |
| SCHEMBL16532678 | 0.78 | ELANE (0.47) | ELANEMAP3K14ALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL16532662 | 0.77 | MAP3K14 (0.81) | MAP3K14 | |
| SCHEMBL18673435 | 0.76 | ELANE (0.66) | ELANEALDH1A1NPC1POLBSMN1; SMN2 | |
| SCHEMBL16517675 | 0.76 | MAP3K14 (0.48) | MAP3K14ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL16532689 | 0.76 | MAP3K14 (0.46) | ELANEMAP3K14ALDH1A1NPC1ADORA1 | |
| SCHEMBL16532652 | 0.75 | ADORA1 (0.46) | ELANEMAP3K14ALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL16517101 | 0.72 | ELANE (0.47) | ELANEMAP3K14ALDH1A1NPC1NPSR1 | |
| SCHEMBL18673460 | 0.71 | GAA (0.52) | ELANEMAP3K14ALDH1A1 | |
| SCHEMBL22920626 | 0.69 | ALDH1A1 (0.52) | ELANEALDH1A1NPC1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145034-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-9605005-B2 | Alkynyl alcohols and methods of use | GENENTECH, INC. (US) | 2017-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145034-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, RELA | ELANE 1188/4885MAP3K14 514/4885ALDH1A1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.